No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
SNY Sanofi
- 48.760
- -1.600-3.18%
Trading May 23 12:11 ET
121.87BMarket Cap24.97P/E (TTM)
49.610High48.700Low1.24MVolume49.500Open50.360Pre Close60.94MTurnover0.06%Turnover Ratio20.95P/E (Static)2.50BShares53.45452wk High1.52P/B107.17BFloat Cap40.89652wk Low1.91Dividend TTM2.20BShs Float53.460Historical High3.92%Div YieldTTM1.81%Amplitude8.844Historical Low49.294Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Tech Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading
Tech stocks led European equities traded in the US as American depositary receipts modestly higher Thursday morning, rising 0.4% to 1,428.1 on the S&P Europe Select ADR Index. From continental Europe,
Sanofi Reports Positive Data From Phase II Asthma Treatment Trial
Pfizer, Moderna in Talks With HHS Over Avian Flu Vaccine: Report
First Advanced Oral Treatment For Asthma - Sanofi's Investigational Drug Shows Potential
Wednesday, Sanofi SA (NASDAQ:SNY) reported results from the Phase 2 study of oral rilzabrutinib in adult patients with uncontrolled moderate-to-severe asthma.Two doses of rilzabrutinib, 800 mg daily a
Sanofi Drug Shows Promise in Asthma After Blood Disorder Success
Express News | Sanofi Shares Are Trading Higher Following New Phase 2 Results for Rilzabrutinib in Moderate-to-severe Asthma, Showing Potential for Advancement to Phase 3
Comments
$Sanofi(SNY.US$
Alright, folks, let’s dive into the world of biotech drama. Shares of Novavax (NVAX) have been on a tear, continuing their climb on Monday after the company dropped some major news last week. They announced a licensing deal with Sanofi, and the stock shot up 47.6%, closing at $13.11. That's the highest it's been since December 2022.
But wait, there's more! Novavax shares had already doubled last Friday on this news, and over the past three months, t...
Alright, folks, let’s dive into the world of biotech drama. Shares of Novavax (NVAX) have been on a tear, continuing their climb on Monday after the company dropped some major news last week. They announced a licensing deal with Sanofi, and the stock shot up 47.6%, closing at $13.11. That's the highest it's been since December 2022.
But wait, there's more! Novavax shares had already doubled last Friday on this news, and over the past three months, t...
6
Meme stock volatility hit the market Monday, sending indexes higher, but shortly before noon EST, the market boomeranged back down. Just after the closing bell, the $S&P 500 Index(.SPX.US$ had fallen flatly 0.02%, the $Dow Jones Industrial Average(.DJI.US$ also declined 0.17%, and the $Nasdaq Composite Index(.IXIC.US$ climbed 0.28%.
MACRO
This week, investors can expect macroeconomic data prints in the form of PPI on Tuesday, and CPI prints Wednesd...
MACRO
This week, investors can expect macroeconomic data prints in the form of PPI on Tuesday, and CPI prints Wednesd...
+1
28
4
$Novavax(NVAX.US$
👉 Key Highlights:
📍 Novavax's shares jump 120% in premarket trading after announcing a deal with Sanofi.
📍 Partnership to co-commercialize Covid vaccine and develop combination flu shots.
📍 Sanofi to make an upfront payment of $500 million to Novavax, with potential for up to $700 million more.
📍 Deal includes royalties and up to $200 million in additional milestones.
📍 Sanofi acquires less than ...
👉 Key Highlights:
📍 Novavax's shares jump 120% in premarket trading after announcing a deal with Sanofi.
📍 Partnership to co-commercialize Covid vaccine and develop combination flu shots.
📍 Sanofi to make an upfront payment of $500 million to Novavax, with potential for up to $700 million more.
📍 Deal includes royalties and up to $200 million in additional milestones.
📍 Sanofi acquires less than ...
3
3
Top 10 drug companies raked in NEARLY TRIPLE the revenue in 2023 ($491B) vs 2013 ($165B) 2013 vs. 2023.
$AbbVie(ABBV.US$ +189%
$Bristol-Myers Squibb(BMY.US$ +175%
$Johnson & Johnson(JNJ.US$ +95%
$AstraZeneca(AZN.US$ +78%
$NVM +45%
$Merck & Co(MRK.US$ +37%
$ROCHE HOLDING AG(RHHBY.US$ +27%
$Pfizer(PFE.US$ +13%
$GlaxoSmithKline(GSK.US$ +13%
----- $SPDR S&P 500 ETF(SPY.US$ +12% -----
$Sanofi(SNY.US$ +3%
Source: Arjun Murthy on the HR app!
$AbbVie(ABBV.US$ +189%
$Bristol-Myers Squibb(BMY.US$ +175%
$Johnson & Johnson(JNJ.US$ +95%
$AstraZeneca(AZN.US$ +78%
$NVM +45%
$Merck & Co(MRK.US$ +37%
$ROCHE HOLDING AG(RHHBY.US$ +27%
$Pfizer(PFE.US$ +13%
$GlaxoSmithKline(GSK.US$ +13%
----- $SPDR S&P 500 ETF(SPY.US$ +12% -----
$Sanofi(SNY.US$ +3%
Source: Arjun Murthy on the HR app!
4
1
📌Last week’s PDUFAs:
$Heron Therapeutics(HRTX.US$ : Approved 1/23 🎉
⇒ ZYNRELEF
⇒ Postoperative pain
⇒ sNDA
⇒ PDUFA: 01/23/24
$Liquidia(LQDA.US$ : NDA review ongoing 🤔
⇒ YUTREPIA
⇒ PH-ILD
⇒ NDA
⇒ PDUFA: 01/24/24
$Theratechnologies(THTX.US$ : CRL 1/24 🙁
⇒ F8 Formulation of Tesamorelin
⇒ Excess abdominal fat in adults w/ HIV
⇒ sBLA
⇒ PDUFA: 01/22/24
$Sanofi(SNY.US$ & $Regeneron Pharmaceuticals(REGN.US$ : Approved 1/25 🎉
⇒ Dupixent
⇒ Eosinophilic esophagitis (pedia)
⇒ sB...
$Heron Therapeutics(HRTX.US$ : Approved 1/23 🎉
⇒ ZYNRELEF
⇒ Postoperative pain
⇒ sNDA
⇒ PDUFA: 01/23/24
$Liquidia(LQDA.US$ : NDA review ongoing 🤔
⇒ YUTREPIA
⇒ PH-ILD
⇒ NDA
⇒ PDUFA: 01/24/24
$Theratechnologies(THTX.US$ : CRL 1/24 🙁
⇒ F8 Formulation of Tesamorelin
⇒ Excess abdominal fat in adults w/ HIV
⇒ sBLA
⇒ PDUFA: 01/22/24
$Sanofi(SNY.US$ & $Regeneron Pharmaceuticals(REGN.US$ : Approved 1/25 🎉
⇒ Dupixent
⇒ Eosinophilic esophagitis (pedia)
⇒ sB...
12
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg